TY - JOUR
TI - Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy
AU - Tzaida, O.
AU - Gogas, H.
AU - Dafni, U.
AU - Kyroudi, A.
AU - Papaspyrou, I.
AU - Kyriakou, V.
AU - Malamou-Mitsi, V.
AU - Alamani, M.
AU - Skopa, C.
AU - Kostopoulos, I.
AU - Kastritis, E.
AU - Pectasides, D.
AU - Briasoulis, E.
AU - Kalofonos, H.P.
AU - Aravantinos, G.
AU - Fountzilas, G.
AU - Arapantoni-Dadioti, P.
JO - DIAGNOSTIC ONCOLOGY
PY - 2008
VL - 72
TODO - 5-6
SP - 388-396
PB - 
SN - null
TODO - 10.1159/000113148
TODO - antineoplastic agent;  cyclophosphamide;  epidermal growth factor receptor;  epidermal growth factor receptor 2;  epirubicin;  fluorouracil;  methotrexate;  paclitaxel;  protein p53;  tamoxifen, adult;  aged;  article;  breast cancer;  cancer chemotherapy;  cancer growth;  cancer risk;  clinical evaluation;  clinical trial;  controlled clinical trial;  controlled study;  disease free survival;  female;  high risk patient;  human;  immunohistochemistry;  major clinical study;  multiple cycle treatment;  priority journal;  prognosis;  protein expression;  protein protein interaction;  randomized controlled trial;  treatment outcome, Adult;  Aged;  Antineoplastic Combined Chemotherapy Protocols;  Breast Neoplasms;  Chemotherapy, Adjuvant;  Combined Modality Therapy;  Cyclophosphamide;  Disease-Free Survival;  Epirubicin;  Female;  Fluorouracil;  Genes, erbB-1;  Humans;  Immunohistochemistry;  Methotrexate;  Middle Aged;  Paclitaxel;  Predictive Value of Tests;  Prognosis
TODO - Background: To assess the prognostic and predictive significance of HER-1/EGFR protein levels in high-risk patients with breast cancer treated with dose-dense sequential adjuvant chemotherapy. Methods: 595 high-risk breast cancer patients were treated with adjuvant anthracycline-based dose-dense sequential chemotherapy (E-CMF vs. E-T-CMF). Disease-free survival (DFS) was the primary end point. HER-1/EGFR was assessed by immunohistochemistry (IHC) in 312 patients. Results: HER-1/EGFR expression was detected in 54 of 312 patients (17%). Positive expression of HER-1/EGFR was significantly associated with negative receptor status (52 vs. 17%, p < 0.001), worse histological grade (70 vs. 45%, p = 0.001), HER-2 overexpression (46 vs. 27%, p = 0.01) and positive p53 expression (48 vs. 19%, p < 0.001). With a median follow-up of 7 years, the total number of relapses was 105 (34%), and the total number of deaths 69 (22%). The analysis for DFS provides significant evidence that the HER-1/EGFR effect on the risk of disease progression was different according to treatment (interaction p = 0.02). Regarding overall survival, a trend towards a significant difference for an interaction of HER-1/EGFR and treatment was found (p = 0.07). Conclusion: The present study demonstrated a differential effect of positive HER-1/EGFR expression in the two treatment groups, with HER-1/EGFR being a negative prognostic marker in the absence of paclitaxel. Copyright © 2008 S. Karger AG.
ER -